| 1.095 0.085 (8.42%) | 10-21 12:48 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.54  |
1-year : | 1.78 |
| Resists | First : | 1.32 |
Second : | 1.52 |
| Pivot price | 1.12 |
|||
| Supports | First : | 0.99 | Second : | 0.82 |
| MAs | MA(5) : | 1.06 |
MA(20) : | 1.18 |
| MA(100) : | 3.34 |
MA(250) : | 7.95 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 10.3 |
D(3) : | 9.4 |
| RSI | RSI(14): 40.8 |
|||
| 52-week | High : | 27.36 | Low : | 0.99 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VRXA ] has closed above bottom band by 41.3%. Bollinger Bands are 94.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 72 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.09 - 1.1 | 1.1 - 1.1 |
| Low: | 0.98 - 0.98 | 0.98 - 0.99 |
| Close: | 1 - 1.01 | 1.01 - 1.02 |
Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company was founded in 2021 and is based in Heidelberg, Germany.
Wed, 21 Oct 2026
VERAXA Biotech (NASDAQ: VRXA) Expands Human-Relevant Testing Strategy to Advance Antibody-Based Cancer Pi - Benzinga
Tue, 13 Oct 2026
VERAXA Biotech (NASDAQ: VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at Worl - Benzinga
Tue, 13 Oct 2026
VERAXA Biotech AG (VRXA) Reports First In Vivo Proof-of-Concept for BiTAC-ADC - TradingView
Wed, 07 Oct 2026
VERAXA Biotech (VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing - Yahoo Finance
Tue, 29 Sep 2026
Veraxa Biotech AG (VRXA) Stock Price & News - Syfe
Thu, 24 Sep 2026
VERAXA Biotech (VRXA) Advances Oncology Pipeline as Xlife Sciences Reports First-Half Progress - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 141 (M) |
| Held by Insiders | 3.84e+006 (%) |
| Held by Institutions | 69.9 (%) |
| Shares Short | 203 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.424e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -282 % |
| Return on Assets (ttm) | 662.7 % |
| Return on Equity (ttm) | -50 % |
| Qtrly Rev. Growth | 23430 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -4586.43 |
| EBITDA (p.s.) | 81368.4 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | -0.17 |
| Dividend | 0 |
| Forward Dividend | 235020 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|